CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$32.58 USD
-1.71 (-4.99%)
Updated May 31, 2024 04:00 PM ET
After-Market: $32.59 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGON 32.58 -1.71(-4.99%)
Will CGON be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CGON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGON
How to Find Up-and-Coming Stocks to Buy Right Now
CGON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGON
Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
CG Oncology climbs 10% on Phase 2 data for bladder cancer drug
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
Decoding 10 Analyst Evaluations For CG Oncology